[Group News] Chi Heal Bio Supports Partner in Securing Approval for Cefotaxime Sodium for Injection in Generic Consistency Evaluation

Drug Overview

Cefotaxime Sodium is a third-generation cephalosporin antibiotic belonging to the β-lactam class. It exerts its antibacterial effects primarily by inhibiting bacterial cell wall synthesis. Discovered in 1975 by the French Roussel-Uclaf Institute (now part of Sanofi) and co-developed with Germany’s Hoechst (also now Sanofi), its structure incorporates an aminothiazolyl cis-methoxyimino acetyl group at the 7-position of 7-aminocephalosporanic acid. This modification enhances β-lactamase stability, broadens antibacterial coverage, and boosts antimicrobial potency, leading to its commercialization in the 1980s.Recognized as one of the safest and most effective antibiotics, cefotaxime sodium is listed on the WHO Essential Medicines List. Currently, Cefotaxime Sodium for Injection is marketed in multiple countries/regions, with key markets including Germany, France, and Italy. It is primarily used to treat severe acute/chronic bacterial infections caused by cefotaxime-sensitive pathogens.